

Match Overview



1	CrossCheck 35 words Hong, Suk Jin, and Byung-Ho Choe. "Strategy to Overcome Drug Resistance That Develops during Treatment of Ch...	1%
2	CrossCheck 20 words Maureen M. Jonas. "Treatment of chronic hepatitis B in children: Current status", Current Hepatitis Reports, 02/2008	<1%
3	Internet 19 words crawled on 24-Apr-2014 www.ashm.org.au	<1%
4	CrossCheck 18 words Ann W. Walsh. "Mechanistic Characterization and Molecular Modeling of Hepatitis B Virus Polymerase Resistance to	<1%
5	Internet 17 words crawled on 27-Jun-2014 www.liver.ca	<1%
6	CrossCheck 15 words Sae Hwan Lee. "Pre-existing YMDD mutants in treatment-naïve patients with chronic hepatitis B are not selected dur...	<1%
7	CrossCheck 13 words Morris Sherman. "Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and	<1%
8	CrossCheck 13 words Corina Hartman. "Long-term Lamivudine Therapy for Chronic Hepatitis B Infection in Children Unresponsive to Inter...	<1%
9	CrossCheck 13 words Sokal, E.M., M. Paganelli, S. Wirth, P. Socha, P. Vajro, F. Lacaille, D. Kelly, and G. Mieli-Vergani. "Management of	<1%

Name of journal: World Journal of Hepatology

ESPS Manuscript NO: 13536

Columns: MINIREVIEWS

40 Lamivudine Resistance in Children with Chronic Hepatitis B

Erhun Kasirga

Abstract

Currently, although lamivudine (LAM) has a low genetic barrier, only interferon-alpha (IFN-alpha) and LAM are available as a first-line treatment in children with chronic hepatitis B (CHB). Lamivudine is a potent inhibitor of hepatitis B virus-deoxyribonucleic acid (HBV-DNA) polymerase replication by termination of the proviral HBV-DNA chain. Lamivudine has a good safety and tolerability profile in CHB patients with hepatic decompensation. However, the main disadvantages of this HBV reverse transcriptase inhibitor are: 1) pre-existing covalently closed circular DNA (cccDNA) cannot be eradicated by lamivudine, thus relapse after therapy withdrawal is frequent; and 2) although the longer LAM treatment induced the higher seroconversion rate, the risk of viral resistance increased through the selection of YMDD (tyrosine, methionine, aspartate, aspartate) motif. Insufficient suppression of viral replication leads to the emergence of resistant strains that could result in virological breakthrough which is usually followed by biochemical breakthrough. Mutant strains affects additional resistance and cross resistance, leading to drug resistance in a significant number of CHB patients. In this case, efficacy of more powerful antiviral agents with higher genetic barrier